148 related articles for article (PubMed ID: 37557181)
1. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
2. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
4. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.
Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H
Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135
[TBL] [Abstract][Full Text] [Related]
5. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract][Full Text] [Related]
6. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
7. Histone acetylation and histone acetyltransferases show significant alterations in human abdominal aortic aneurysm.
Han Y; Tanios F; Reeps C; Zhang J; Schwamborn K; Eckstein HH; Zernecke A; Pelisek J
Clin Epigenetics; 2016; 8():3. PubMed ID: 26767057
[TBL] [Abstract][Full Text] [Related]
8. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract][Full Text] [Related]
9. KAT6A Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative Breast Cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
[TBL] [Abstract][Full Text] [Related]
10. The histone acetyltransferase KAT6B is required for hematopoietic stem cell development and function.
Bergamasco MI; Ranathunga N; Abeysekera W; Li-Wai-Suen CSN; Garnham AL; Willis SN; McRae HM; Yang Y; D'Amico A; Di Rago L; Wilcox S; Nutt SL; Alexander WS; Smyth GK; Voss AK; Thomas T
Stem Cell Reports; 2024 Apr; 19(4):469-485. PubMed ID: 38518784
[TBL] [Abstract][Full Text] [Related]
11. HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.
Jeselsohn R; Polyak K
Cell Chem Biol; 2023 Oct; 30(10):1183-1185. PubMed ID: 37863030
[TBL] [Abstract][Full Text] [Related]
12. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
Yu L; Liang Y; Cao X; Wang X; Gao H; Lin SY; Schiff R; Wang XS; Li K
Oncogene; 2017 May; 36(20):2910-2918. PubMed ID: 27893709
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A.
Leaver DJ; Cleary B; Nguyen N; Priebbenow DL; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Sabroux HJ; Falk H; Chung MC; Hermans SJ; Parker MW; Thomas T; Baell JB
J Med Chem; 2019 Aug; 62(15):7146-7159. PubMed ID: 31256587
[TBL] [Abstract][Full Text] [Related]
14. KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster.
Singh M; Spendlove SJ; Wei A; Bondhus LM; Nava AA; de L Vitorino FN; Amano S; Lee J; Echeverria G; Gomez D; Garcia BA; Arboleda VA
Hum Genet; 2023 Dec; 142(12):1705-1720. PubMed ID: 37861717
[TBL] [Abstract][Full Text] [Related]
15. Pantothenate and L-Carnitine Supplementation Improves Pathological Alterations in Cellular Models of KAT6A Syndrome.
Munuera-Cabeza M; Álvarez-Córdoba M; Suárez-Rivero JM; Povea-Cabello S; Villalón-García I; Talaverón-Rey M; Suárez-Carrillo A; Reche-López D; Cilleros-Holgado P; Piñero-Pérez R; Sánchez-Alcázar JA
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553567
[TBL] [Abstract][Full Text] [Related]
16. Deficient histone H3 propionylation by BRPF1-KAT6 complexes in neurodevelopmental disorders and cancer.
Yan K; Rousseau J; Machol K; Cross LA; Agre KE; Gibson CF; Goverde A; Engleman KL; Verdin H; De Baere E; Potocki L; Zhou D; Cadieux-Dion M; Bellus GA; Wagner MD; Hale RJ; Esber N; Riley AF; Solomon BD; Cho MT; McWalter K; Eyal R; Hainlen MK; Mendelsohn BA; Porter HM; Lanpher BC; Lewis AM; Savatt J; Thiffault I; Callewaert B; Campeau PM; Yang XJ
Sci Adv; 2020 Jan; 6(4):eaax0021. PubMed ID: 32010779
[TBL] [Abstract][Full Text] [Related]
17. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract][Full Text] [Related]
18. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain.
Weber LM; Jia Y; Stielow B; Gisselbrecht SS; Cao Y; Ren Y; Rohner I; King J; Rothman E; Fischer S; Simon C; Forné I; Nist A; Stiewe T; Bulyk ML; Wang Z; Liefke R
Nucleic Acids Res; 2023 Jan; 51(2):574-594. PubMed ID: 36537216
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation episignatures are sensitive and specific biomarkers for detection of patients with
Vos N; Reilly J; Elting MW; Campeau PM; Coman D; Stark Z; Tan TY; Amor DJ; Kaur S; StJohn M; Morgan AT; Kamien BA; Patel C; Tedder ML; Merla G; Prontera P; Castori M; Muru K; Collins F; Christodoulou J; Smith J; Zeev BB; Murgia A; Leonardi E; Esber N; Martinez-Monseny A; Casas-Alba D; Wallis M; Mannens M; Levy MA; Relator R; Alders M; Sadikovic B
Epigenomics; 2023 Mar; 15(6):351-367. PubMed ID: 37249002
[TBL] [Abstract][Full Text] [Related]
20. Lysine acetyltransferase 6A maintains CD4
Fu JY; Huang SJ; Wang BL; Yin JH; Chen CY; Xu JB; Chen YL; Xu S; Dong T; Zhou HN; Ma XY; Pu YP; Li H; Yang XJ; Xie LS; Wang ZJ; Luo Q; Shao YX; Ye L; Zong ZR; Wei XD; Xiao WW; Niu ST; Liu YM; Xu HP; Yu CQ; Duan SZ; Zheng LY
Cell Metab; 2024 Mar; 36(3):557-574.e10. PubMed ID: 38237601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
